Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association

Salvatore, Lisa; Imperatori, Marco; Arnoldi, Ermenegildo; Carnaghi, Carlo; Cordio, S.; Cosimelli, Maurizio; Cremolini, Chiara; Maiello, Evaristo; Martinelli, Erika; Normanno, Nicola; Sciallero, Stefania; Cannizzaro, Renato; Musio, Daniela; Cinquini, Michela; Moschetti, Ivan; Fittipaldo, Veronica Andrea; Aprile, Giuseppe; Beretta, Giordano Domenico

doi:10.1136/esmoopen-2020-001001

Cited by 12 publications

(5 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After filtering through reviews of titles and abstracts, 63 records were appraised for eligibility. Finally, 59 guidelines were included (45 CPGs [30–88] and 14 CSs [42, 44–46, 49, 56–58, 67, 75, 80, 83, 86, 88]) for the final full‐text appraisal (Table 1). Seven CPGs and no CSs (11.9%) were in French [37–40], Slovenian [77], Norwegian [68] and Croatian [82]; a total of 52/59 (88.1%) documents were in English.…”

Section: Resultsmentioning

confidence: 99%

Guidance documents for colorectal and anal cancer treatment: A systematic quality and reporting assessment

et al. 2022

View full text Add to dashboard Cite

Aim Evidence‐based medicine is essential for clinical practice. Clinical practice guidelines (CPGs) and consensus statements (CSs) ought to follow a consistent methodology to underpin high‐quality healthcare. We systematically analysed the quality and reporting of colorectal (CRC) and anal cancer CPGs and CSs. Methods Embase, MEDLINE, Scopus, Web of Science, the Cochrane Database of Systematic Reviews and online sources (59 professional society websites and eight guideline databases) were systematically searched following prospective registration (PROSPERO no. CRD42021286146) by two reviewers independently, without language restrictions. CPGs and CSs about CRC and anal cancer treatment were included from January 2018 to November 2021 and were assessed using the AGREE II tool (per cent of maximum score) and the RIGHT tool (per cent of total 35 items) for quality and reporting respectively. Results The median overall quality and reporting of the 59 guidelines analysed were 55.0% (interquartile range 47.0–62.0) and 58% (interquartile range 50.0–67.9), respectively, with a proportion scoring less than half (<50%) for quality (20/59, 33.9%) and reporting (15/59, 25.4%). Guidance reported that following AGREE II methodology scored better on average than that without (AGREE II 77.7% vs. 47.6%, P = 0.001; RIGHT 50.0% vs. 33.9%, P = 0.001). Guidelines based on systematic reviews had better quality and reporting on average than those based on consensus (AGREE II 56.5% vs. 46.6%, P = 0.001; RIGHT 36.9% vs. 35.4%, P = 0.019). Conclusion The quality and reporting of colorectal and anal cancer treatment CPGs and CSs were poor. Despite AGREE II and RIGHT inherent methodological limitations, few high‐quality guidelines were found. Despite wide variability in scoring different domains, they merit urgent improvement in all areas. It has also been demonstrated that CPGs and CSs should be underpinned by systematic reviews collecting the best available clinical research findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Guidance documents for colorectal and anal cancer treatment: A systematic quality and reporting assessment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…After clinical examination, a correct preoperative assessment includes transrectal ultrasonography and pelvic MRI, to assess the lymph node status and bowel wall invasion [2,3].…”

Section: Dear Editormentioning

confidence: 99%

“…After clinical examination, a correct preoperative assessment includes transrectal ultrasonography and pelvic MRI, to assess the lymph node status and bowel wall invasion [2,3]. type of minimally invasive approach is still debated, and evidence supporting the use of a particular approach is poor.…”

Section: Dear Editormentioning

confidence: 99%

Transanal minimally invasive approach for early giant rectal tumour – a video‐vignette

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Based on clinical stages and the nature of colorectal cancer, a number of treatment strategies have been developed, such as a multimodal approach comprising surgical resection followed by chemotherapy with monoclonal antibodies or proteins against vascular endothelial growth factor and epidermal growth receptor [14,15]. Furthermore, alternative therapies, including the use of anti-inflammatory medications, probiotics, and gold nanoparticle-based pharmaceuticals, are now under research to improve treatment effectiveness and lessen side effects compared to conventional chemotherapy [16,17].…”

Section: Introductionmentioning

confidence: 99%

Attenuating Colorectal Cancer Using Nine Cultivars of Australian Lupin Seeds: Apoptosis Induction Triggered by Mitochondrial Reactive Oxygen Species Generation and Caspases-3/7 Activation

Mazumder,

Aktar,

Ramasamy

et al. 2023

Cells

View full text Add to dashboard Cite

As Australian lupin cultivars are rich sources of polyphenols, dietary fibers, high-quality proteins, and abundant bioactive compounds with significant antioxidant, antidiabetic, and anticancer activities, this research work is aimed at investigating the colon cancer alleviation activity of nine cultivars of lupin seeds on HCT116 and HT29 colon carcinoma cell lines through anti-proliferation assay, measurement of apoptosis, and identification of the mechanism of apoptosis. Nine cultivars were pre-screened for anti-proliferation of HCT116 and HT29 cells along with consideration of the impact of heat processing on cancer cell viability. Mandelup and Jurien showed significant inhibition of HCT116 cells, whereas the highest inhibition of HT29 cell proliferation was attained by Jurien and Mandelup. Processing decreased the anti-proliferation activity drastically. Lupin cultivars Mandelup, Barlock, and Jurien (dose: 300 μg/mL) induced early and late apoptosis of colon cancer cells in Annexin V-FITC assay. The mechanism of apoptosis was explored, which involves boosting of caspases-3/7 activation and intracellular reactive oxygen species (ROS) generation in HCT116 cells (Mandelup and Barlock) and HT29 cells (Jurien and Mandelup). Thus, the findings showed that lupin cultivars arrest cell cycles by inducing apoptosis of colorectal carcinoma cells triggered by elevated ROS generation and caspases-3/7 activation.

show abstract

Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association

Cited by 12 publications

References 73 publications

Guidance documents for colorectal and anal cancer treatment: A systematic quality and reporting assessment

Guidance documents for colorectal and anal cancer treatment: A systematic quality and reporting assessment

Transanal minimally invasive approach for early giant rectal tumour – a video‐vignette

Attenuating Colorectal Cancer Using Nine Cultivars of Australian Lupin Seeds: Apoptosis Induction Triggered by Mitochondrial Reactive Oxygen Species Generation and Caspases-3/7 Activation

Contact Info

Product

Resources

About